Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.51 HKD | 0.00% | -1.92% | -22.73% |
Apr. 22 | Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug | MT |
Apr. 17 | Future Data Group Limited Announces Changes to its Board | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 77.6 | 56 | 48 | 108 | 156 | 360.8 |
Enterprise Value (EV) 1 | -39.77 | -42.16 | -17.98 | 72.64 | 99.05 | 238.5 |
P/E ratio | 13.5 x | 12.8 x | 6.09 x | 14.9 x | -50.3 x | -19.9 x |
Yield | 7.58% | - | - | - | - | - |
Capitalization / Revenue | 0.13 x | 0.09 x | 0.07 x | 0.15 x | 0.25 x | 0.75 x |
EV / Revenue | -0.07 x | -0.07 x | -0.03 x | 0.1 x | 0.16 x | 0.49 x |
EV / EBITDA | -3.02 x | -10.3 x | -2.78 x | 4.59 x | -49.2 x | -20.3 x |
EV / FCF | 11.1 x | -26.9 x | 0.6 x | -2.19 x | 2.6 x | 142 x |
FCF Yield | 8.97% | -3.72% | 167% | -45.7% | 38.5% | 0.7% |
Price to Book | 0.57 x | 0.43 x | 0.34 x | 0.77 x | 1.18 x | 1.98 x |
Nbr of stocks (in thousands) | 400,000 | 400,000 | 400,000 | 400,000 | 400,000 | 546,680 |
Reference price 2 | 0.1940 | 0.1400 | 0.1200 | 0.2700 | 0.3900 | 0.6600 |
Announcement Date | 3/28/19 | 3/31/20 | 3/30/21 | 3/30/22 | 3/28/23 | 4/29/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 605.2 | 646.5 | 679.1 | 720.6 | 617.6 | 482 |
EBITDA 1 | 13.18 | 4.079 | 6.464 | 15.84 | -2.014 | -11.75 |
EBIT 1 | 9.212 | 0.732 | 4.126 | 14.03 | -3.991 | -14.48 |
Operating Margin | 1.52% | 0.11% | 0.61% | 1.95% | -0.65% | -3% |
Earnings before Tax (EBT) 1 | 10.35 | 4.261 | 9.027 | 15.7 | -2.453 | -21.04 |
Net income 1 | 5.758 | 4.373 | 7.876 | 7.25 | -3.346 | -16.37 |
Net margin | 0.95% | 0.68% | 1.16% | 1.01% | -0.54% | -3.4% |
EPS 2 | 0.0144 | 0.0109 | 0.0197 | 0.0181 | -0.007747 | -0.0332 |
Free Cash Flow 1 | -3.567 | 1.568 | -30.12 | -33.22 | 38.17 | 1.677 |
FCF margin | -0.59% | 0.24% | -4.44% | -4.61% | 6.18% | 0.35% |
FCF Conversion (EBITDA) | - | 38.45% | - | - | - | - |
FCF Conversion (Net income) | - | 35.86% | - | - | - | - |
Dividend per Share 2 | 0.0147 | - | - | - | - | - |
Announcement Date | 3/28/19 | 3/31/20 | 3/30/21 | 3/30/22 | 3/28/23 | 4/29/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 117 | 98.2 | 66 | 35.4 | 56.9 | 122 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -3.57 | 1.57 | -30.1 | -33.2 | 38.2 | 1.68 |
ROE (net income / shareholders' equity) | 4.2% | 3.04% | 5.49% | 6.09% | -2.88% | -12.1% |
ROA (Net income/ Total Assets) | 1.73% | 0.14% | 0.86% | 2.68% | -0.72% | -2.94% |
Assets 1 | 333.1 | 3,110 | 917.3 | 270.5 | 465.7 | 557.3 |
Book Value Per Share 2 | 0.3400 | 0.3200 | 0.3600 | 0.3500 | 0.3300 | 0.3300 |
Cash Flow per Share 2 | 0.3400 | 0.2900 | 0.2400 | 0.3100 | 0.3100 | 0.2200 |
Capex 1 | 3.07 | 1.52 | 17.4 | 11.1 | 21.9 | 4.47 |
Capex / Sales | 0.51% | 0.23% | 2.56% | 1.54% | 3.54% | 0.93% |
Announcement Date | 3/28/19 | 3/31/20 | 3/30/21 | 3/30/22 | 3/28/23 | 4/29/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.73% | 35.71M | |
+6.02% | 36.19B | |
+1.74% | 15.58B | |
-2.65% | 9.37B | |
+1.22% | 7.09B | |
+13.81% | 5.49B | |
-48.45% | 4.25B | |
+7.32% | 2.87B | |
-15.88% | 2.3B | |
-5.42% | 2.15B |
- Stock Market
- Equities
- 8229 Stock
- Financials Future Data Group Limited